v3.25.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Research and development, net of grants $ 15,745 $ 16,968
General and administrative, net of grants 8,932 9,997
Total operating expenses 24,677 26,965
Loss from operations (24,677) (26,965)
Other income (expense), net 1,191 1,313
Net loss $ (23,486) $ (25,652)
Net loss per common share - basic (in dollars per share) $ (0.43) $ (0.5)
Net loss per common share - diluted (in dollars per share) $ (0.43) $ (0.5)
Weighted average shares outstanding - basic (in shares) 54,981 50,853
Weighted average shares outstanding - diluted (in shares) 54,981 50,853

Source